Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Roche, Vertex, Romark report HCV data

A trio of companies announced Phase II results for their HCV molecules on Friday. Roche (SWX:ROG) said up to 81% of patients receiving 1,500 mg of its polymerase inhibitor

Read the full 295 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE